NCT06247085Phase 3Recruiting

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

Study sponsor: Travere Therapeutics, Inc. · TVTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-08Estimated
Enrollment · participants70Estimated
Source updated2026-11-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in plasma tHcy levels. After: Measure: Change from baseline in plasma tHcy levels - Weeks 6 to 12.

Primary completion date changed

Before: Dec 2025. After: Aug 2027.

Recruitment status changed

Before: Active not recruiting. After: Recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview